Literature DB >> 1346366

Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer.

C Wright1, S Nicholson, B Angus, J R Sainsbury, J Farndon, J Cairns, A L Harris, C H Horne.   

Abstract

Of 221 patients with breast cancer of known epidermal growth factor receptor (EGFR) and oestrogen receptor (ER) status, 99 had developed recurrences during the period of follow-up (range 3-60 months, median 24 months). Of these, 72 received endocrine therapy as first-line treatment for relapse. Immunohistochemical assessment of c-erbB-2 protein product expression was made using paraffin-embedded tumour tissue from 65 of these 72 patients. Including patients whose disease remained stable for more than 6 months with those showing an objective response (CR or PR for more than 3 months), only one (7%) of 14 c-erbB-2 positive tumours responded to endocrine manipulation compared with 19 (37%) of 51 c-erbB-2 negative tumours (P less than 0.05). Coexpression of c-erbB-2 reduced the response rate of ER positive patients from 48% to 20% and of ER negative cases from 27% to 0% (P less than 0.01). EGFR and c-erbB-2 protein appeared to have additive effects in reducing the likelihood of response, and none of eight patients with EGFR positive, c-erbB-2 positive tumours derived benefit from endocrine therapy. The results of this study suggest that c-erbB-2 protein overexpression, a marker of poor prognosis in breast cancer, is associated with a lack of response to endocrine therapy on relapse, and particularly in combination with EGFR may be useful in directing therapeutic choices.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1346366      PMCID: PMC1977338          DOI: 10.1038/bjc.1992.22

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  20 in total

Review 1.  Who needs steroid receptor assays?

Authors:  D M Barnes; I S Fentiman; R R Millis; R D Rubens
Journal:  Lancet       Date:  1989-05-20       Impact factor: 79.321

2.  Expression of epidermal growth factor receptors associated with lack of response to endocrine therapy in recurrent breast cancer.

Authors:  S Nicholson; J R Sainsbury; P Halcrow; P Chambers; J R Farndon; A L Harris
Journal:  Lancet       Date:  1989-01-28       Impact factor: 79.321

3.  Expression of the c-erbB-2 protein in normal and transformed cells.

Authors:  W J Gullick; M S Berger; P L Bennett; J B Rothbard; M D Waterfield
Journal:  Int J Cancer       Date:  1987-08-15       Impact factor: 7.396

4.  Special report. Steriod receptors in breast cancer.

Authors:  E R DeSombre; P P Carbone; E V Jensen; W L McGuire; S A Wells; J L Wittliff; M B Lipsett
Journal:  N Engl J Med       Date:  1979-11-01       Impact factor: 91.245

5.  Relationships between oestrogen receptor,epidermal growth factor receptor, ER-D5, and P24 oestrogen regulated protein in human breast cancer.

Authors:  G M Horne; B Angus; C Wright; G Needham; S Nicholson; A L Harris; B Innes; C H Horne
Journal:  J Pathol       Date:  1988-06       Impact factor: 7.996

6.  Quantitative enzyme-linked immunosorbent assay for the estrogen-regulated Mr 24,000 protein in human breast tumors: correlation with estrogen and progesterone receptors.

Authors:  D J Adams; W L McGuire
Journal:  Cancer Res       Date:  1985-06       Impact factor: 12.701

7.  Expression of epidermal growth factor receptor in breast carcinoma.

Authors:  S Lewis; A Locker; J H Todd; J A Bell; R Nicholson; C W Elston; R W Blamey; I O Ellis
Journal:  J Clin Pathol       Date:  1990-05       Impact factor: 3.411

8.  Quantitative assays of epidermal growth factor receptor in human breast cancer: cut-off points of clinical relevance.

Authors:  S Nicholson; J R Sainsbury; G K Needham; P Chambers; J R Farndon; A L Harris
Journal:  Int J Cancer       Date:  1988-07-15       Impact factor: 7.396

Review 9.  c-erbB-2 oncogene as a prognostic marker in breast cancer.

Authors:  T J Perren
Journal:  Br J Cancer       Date:  1991-03       Impact factor: 7.640

10.  Histochemical studies of human breast cancer using a monoclonal antibody against an oestrogen receptor-related antigen.

Authors:  R A Hawkins; K Sangster; A Krajewski
Journal:  Br J Cancer       Date:  1987-06       Impact factor: 7.640

View more
  62 in total

Review 1.  Monoclonal antibodies.

Authors:  P N Nelson; G M Reynolds; E E Waldron; E Ward; K Giannopoulos; P G Murray
Journal:  Mol Pathol       Date:  2000-06

Review 2.  Transcriptional regulation of type I receptor tyrosine kinases in the mammary gland.

Authors:  N P Bates; H C Hurst
Journal:  J Mammary Gland Biol Neoplasia       Date:  1997-04       Impact factor: 2.673

3.  Prognostic and Predictive Factors for Breast Cancer.

Authors: 
Journal:  Breast Cancer       Date:  1995-10-31       Impact factor: 4.239

Review 4.  The trastuzumab era: current and upcoming targeted HER2+ breast cancer therapies.

Authors:  Jordyn Kreutzfeldt; Brett Rozeboom; Nandini Dey; Pradip De
Journal:  Am J Cancer Res       Date:  2020-04-01       Impact factor: 6.166

Review 5.  Extranuclear signaling by sex steroid receptors and clinical implications in breast cancer.

Authors:  Viroj Boonyaratanakornkit; Nalo Hamilton; Diana C Márquez-Garbán; Prangwan Pateetin; Eileen M McGowan; Richard J Pietras
Journal:  Mol Cell Endocrinol       Date:  2017-11-14       Impact factor: 4.102

6.  IHC for Her2 with CBE356 antibody is a more accurate predictor of Her2 gene amplification by FISH than HercepTest in breast carcinoma.

Authors:  R Ainsworth; J M S Bartlett; J J Going; E A Mallon; A Forsyth; J Richmond; W Angerson; A Watters; B Dunne
Journal:  J Clin Pathol       Date:  2005-10       Impact factor: 3.411

7.  Clinical significance of the quantitative assessment of the cytosolic concentration of HER-2/neu protein in breast cancer by immunoenzymatic assay (ELISA).

Authors:  Maria D Corte; Juan A Rodil; Julio Vázquez; Lucia García; Juan C Rodríguez; Miguel Bongera; José C Fernández; Luis O González; Ma Luz Lamelas; Maite Allende; José L García-Muñiz; Antonio Fueyo; Francisco J Vizoso
Journal:  J Cancer Res Clin Oncol       Date:  2005-11-01       Impact factor: 4.553

8.  MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity in vivo.

Authors:  Y Liu; D el-Ashry; D Chen; I Y Ding; F G Kern
Journal:  Breast Cancer Res Treat       Date:  1995-05       Impact factor: 4.872

9.  Relevance of BCAR4 in tamoxifen resistance and tumour aggressiveness of human breast cancer.

Authors:  M F E Godinho; A M Sieuwerts; M P Look; D Meijer; J A Foekens; L C J Dorssers; T van Agthoven
Journal:  Br J Cancer       Date:  2010-09-21       Impact factor: 7.640

10.  Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu.

Authors:  C C Benz; G K Scott; J C Sarup; R M Johnson; D Tripathy; E Coronado; H M Shepard; C K Osborne
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.